Wellnex led the healthcare market after agreeing to sell Pain Away for up to A$21.3 million. Neuren and Lumos also rose strongly as sales, royalties and product orders improved.
- Wellnex surged 105.36% after its Pain Away sale could repay all A$10.2 million of debt.
- Neuren gained 26.22% as DAYBUE sales rose 30% and its 2026 royalty forecast increased.
- Lumos climbed 25.00% after receiving a US$767,800 FebriDx purchase order.
- Clinical data drove gains for Clarity, Amplia and Dimerix, while several small-cap stocks fell after sharp opening gaps.
- ResMed grew revenue and profit, but its shares fell 3.09% for the week.
Wellnex Life (ASX:WNX) was the clear leader, rising 105.36% after agreeing to sell Pain Away for up to A$21.3 million. Investors welcomed the chance to repay the company’s A$10.2 million debt. Neuren Pharmaceuticals (ASX:NEU) rose 26.22% after DAYBUE sales reached US$125 million in the second quarter. Lumos Diagnostics (ASX:LDX) added 25.00% after securing a US$767,800 order for its rapid infection test.
Debt relief and growing sales
Wellnex’s proposed sale still needs shareholder approval on 8 September. If completed, the deal would leave the company debt-free and focused on contract manufacturing. The buyer, Mentholatum Australasia, will pay part of the consideration later if agreed sales targets are met.
At Neuren, stronger demand for the STIX powder version of DAYBUE lifted sales by 30% from a year earlier. The company raised its 2026 royalty forecast to US$53 million, US$56 million, from US$50 million, US$54 million. Europe could launch the drug in early fourth-quarter 2026, subject to approval. A Japan trial result is expected between September and November.
Clinical results draw buyers
Clarity Pharmaceuticals (ASX:CU6) gained 13.50% after presenting new prostate cancer imaging and treatment data. Its imaging agent found more lesions than some approved alternatives. Next-day scans also helped doctors see more cancer sites. The company is running several large Phase III studies. These studies provide the main evidence needed for approval.
Clarity separately reported early results from its SECuRE treatment study. At the 8 GBq dose, 74% of patients had at least a 25% fall in a prostate cancer blood marker. Complete responses were reported in 31% of assessable patients. The results remain early, and more patients must be treated before the evidence can support approval.
Amplia Therapeutics (ASX:ATX) rose 15.38% after signing a trial deal with Eli Lilly. The companies plan to test narmafotinib with Lilly’s olomorasib in advanced lung cancer from late 2026. The study will examine whether Amplia’s drug can delay resistance to Lilly’s treatment. Lilly will supply olomorasib, reducing the cash Amplia must spend on the study.
Devices, diagnostics and care services
Vitrafy Life Sciences (ASX:VFY) rose 14.00% after revenue grew 80% and its loss fell by half. A US Army study reported 94.4% platelet recovery using Vitrafy’s storage technology. The company also raised A$32 million for US sales and manufacturing. The shares kept rising after reopening from a gap, gaining 10.53% from that new level.
AVITA Medical (ASX:AVH) added 18.92% after lifting 2026 revenue guidance to US$86 million, US$89 million. Second-quarter revenue rose 18% to US$21.7 million, while gross margin reached 81.9%. The company also secured a US$25.5 million US government contract for devices that can reduce the need for skin grafts.
ResMed (ASX:RMD) delivered 10% revenue growth to US$5.7 billion and lifted non-GAAP earnings per share by 17%. It returned US$1 billion to shareholders and raised its quarterly dividend by 10% to US$0.66. The shares still fell -3.09% for the week. Investors may have wanted stronger share-price support after the results, although the briefing gives no specific reason for the fall.
In aged care, Regis Healthcare (ASX:REG) plans to buy Royal Freemasons Homes of Victoria’s home care business. The deal would add about 480 clients and around A$10 million in yearly revenue. Promisia Healthcare (ASX:PHL) also agreed to buy Christchurch’s Chatswood Retirement Village for A$25 million. The purchase would add earnings immediately, subject to shareholder and regulatory approval.
Small-cap gaps need caution
Some smaller healthcare stocks opened well away from their previous closing prices, then moved in different directions. Memphasys (ASX:MEM) fell -20.00% for the week and lost another 14.29% after reopening. The Polish Felix agreement has a minimum value of A$350,000, but investors may be waiting for the three-month evaluation period to produce repeat orders.
ReNerve (ASX:RNV) fell -12.94% despite gaining approval to sell its NervAlign nerve cuff in the Philippines. The stock lost 7.50% after reopening. This shows that a new market approval does not always bring immediate sales.
Neurotech International (ASX:NTI) raised A$4.5 million for its Phase III autism study, but the shares fell -6.25%. The placement priced new shares at A$0.014, which can reduce the value of existing holdings. Tranche two also needs shareholder approval in September.
Other announcements included Control Bionics’ US device registration, Rua Bioscience’s approval for five New Zealand cannabis products, and Imricor’s compatibility declaration from Philips. These approvals and partnerships may support future sales, but the briefings do not yet provide large revenue figures.
Bottom Line?
The next major tests arrive in late 2026. Neuren is waiting for a European decision and a Japan trial result. Amplia plans to start its lung cancer study late in the year, while EVE expects Libbo dosing in the fourth quarter. Wellnex shareholders vote on the Pain Away sale on 8 September, and Integral Diagnostics presents its FY26 results on 25 August.
Questions in the middle?
- Will Wellnex shareholders approve the Pain Away sale, and how quickly can the company repay its debt?
- Can Clarity’s early prostate cancer results hold up as its larger Phase III studies progress?
- Will the new orders, approvals and partnerships produce regular sales or remain one-off announcements?